Ignite Technology Transfer Office

Ask An Expert

Company to create 20 new roles over next two years including a number of specialised material science and extrusion positions 

July 4th 2016

DiaNia Technologies, an innovative materials technology company based in Galway, has secured €2 million in seed-funding to utilise materials science to facilitate the development of disruptive catheter based medical devices.

The investment was led by four key investors - Helen Ryan, Liam Farrissey, Ian Quinn and Gearóid Faherty - and also included the HBAN’s Medtech Business Angel Syndicate and Enterprise Ireland.

The funding will allow DiaNia Technologies to develop and commercialise the first application of its proprietary materials science technology which will enhance the performance and functionality of medical devices resulting in increased patient safety and improved product performance. The technology works by providing in-built low friction at the surface of an extrusion, delivering a paradigm shift in the manipulation of friction on both the inside and outside surface of extruded catheter shafts. This inherent lubricity in the main component of a catheter will eliminate the industry’s need for expensive liners and coatings. It is estimated that the global market potential for this material science technology is in excess of €250 million.

DiaNia Technologies, which is based in NUI Galway’s Business Innovation Centre, expects to create 20 new jobs over the next two years. These will include a number of specialised materials science and extrusion positions as well as roles in quality assurance, regulatory affairs, manufacturing, marketing and finance.

DiaNia Technologies was founded in 2013 by Sinéad Kenny and Mark Mellett, who both have extensive experience in the medical device industry. Sinéad, who has a degree in Materials Science, and a PhD in Biomedical Cements, has previously worked with a host of multinational companies, consultancies and start-ups including Cook Medical, Boston Scientific, Altran and Creganna Medical, developing devices for a wide variety of applications. Mark, a Fellow of the Institute of Chartered Accountants, has held a variety of senior roles in various international companies including Deloitte, Kerry Group, Oracle and more recently Alere, where he is Director of Toll Manufacturing.

Sinead Kenny, CEO of DiaNia Technologies, says: “This €2million investment will accelerate the product arriving to market and will be of benefit to manufacturers and ultimately clients, around the world. Delivering a technology which has the ability to both improve the experience and outcome for the patient as well as making the end device safer and more efficient to produce are the drivers behind our extensive R&D programme. We are excited to be supported by such a knowledgeable group of investors who share our vision of advancing the next generation of medical devices through innovative materials technology.”

Helen Ryan, one of the lead investors in DiaNia Technologies, says: “We are delighted to announce this investment for Galway. There is a strong med-tech knowledge base in the West of Ireland and we’re looking forward to developing the technology to build a long term sustainable company. This is a unique opportunity for materials scientists to show how significant their knowledge is in enabling innovation in the industry.”

Find out more about DiaNia Technologies at

For media enquiries, please contact:
Breda Brown / Catherine Quinn
Unique Media
Tel: 01 5225200 / 086 863 2182 (CQ)

Editorial Notes:

About Sinéad Kenny, CEO of DiaNia Technologies:
Sinéad Kenny has over 15 years’ experience delivering concept medical materials and devices to commercialisation. She has previously worked with a host of multinational companies, consultancies and start-ups including Cook Medical, Boston Scientific, Altran and Creganna Medical, developing devices for a wide variety of applications.
Over a 7 year period at Creganna, Sinéad was responsible for the development of delivery devices for bioactive bone cement to design freeze, validation of a novel blood clot removal device to CE mark approval, the companies first, and managed the design and transfer to production of an unique accessory device for use in the delivery of coronary pacing leads.
With a Materials Science degree (1st Hon/1999), a PhD in Biomedical Materials (2002) and a Masters in Project Management (2009), Sinéad utilises her interdisciplinary background to solve business and technical challenges in order to uncover opportunities linking these two fields.

About the new investors:

  • Helen Ryan ex-CEO of Creganna Medical. Helen is a board member of Enterprise Ireland, Capsos Medical, Galway University Foundation and CURAM.
  • Liam Farrissey is Vice President of product development within Creganna Medical.
  • Ian Quinn was the founder and first CEO of Creganna Medical. Ian is a board member of the Tyndall National Institute and BioInnovate.
  • Gearóid Faherty, founder, ex-Chairman and CEO of Eurand NV, a NASDAQ listed Pharmaceutical Company.

Original content by Unique Media

FaLang translation system by Faboba
  • Archived Press Releases
  • Ignite TTO Info